A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency
Status:
RECRUITING
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
Open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of a single dose of sutacimig monotherapy in participants with congenital FVII deficiency (FVIID).